AI Science Tracker

Cedars-Sinai Medical Center

2 discoveries from 2022 to 2026

Discoveries

AI-derived histology biomarker stratifies first-line chemotherapy outcomes in advanced pancreatic cancer

The CHAI computational-histology platform generated a locked H&E-based biomarker intended to distinguish advanced pancreatic ductal adenocarcinoma patients with differential outcomes on fluoropyrimidine-based versus gemcitabine-based chemotherapy. In an independent validation cohort of 299 patients from the prospectively collected COMPASS and Know Your Tumor cohorts, the 173 patients classified F-pref had longer time to next treatment or death (8.6 vs 7.5 months, P=.035) and overall survival (14.4 vs 11.7 months, P=.003) on F- versus G-based therapy. Among 126 G-pref patients, G-based therapy was associated with longer time to next treatment or death (9.6 vs 7.2 months, P=.038), but not significantly different overall survival.

Technology: Computational Histology Artificial Intelligence (CHAI) platform

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: In an independent validation cohort of 299 patients from the prospectively collected COMPASS and Know Your Tumor cohorts, the 173 patients classified F-pref had longer time to next treatment or death (8.6 vs 7.5 months, P=.035) and overall survival (14.4 vs 11.7 months, P=.003) on F- versus G-based therapy. The locked biomarker was applied to assembled data from prospectively collected cohorts; prospective validation of treatment selection is still needed.
  • Still unknown: Validation used 299 patients in two prospectively collected but nonrandomized cohorts; treatment assignment was not randomized, and the authors also used propensity weighting and target-trial emulation. The primary endpoint was time to next treatment or death, not progression-free survival. In the biomarker’s G-pref subgroup, the OS comparison was not significant. The authors call for further prospective validation before clinical adoption. An earlier CHAI study concerned adjuvant gemcitabine outcomes in resected disease; this entry is limited to the distinct locked first-line fluoropyrimidine-versus-gemcitabine biomarker and external-cohort results in advanced disease.
  • AI role: Deep-learning models segmented H&E biopsy slides and quantified more than 30,000 histomorphologic features. Using the development cohort, the investigators statistically selected and weighted features into a treatment-preference biomarker and locked its threshold before applying it to an independent validation cohort. The platform supplied the image-derived feature measurements used in the biomarker; this is a biomarker-development and validation result, not autonomous treatment assignment.

Evidence sources: https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-02199

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MIMaL predicts and experimentally validates five yeast gene functions from protein–metabolite profiles

MIMaL used tree-based regression and SHAP interpretation on yeast proteome/metabolome measurements, then clustered protein-control profiles across single-gene knockouts. It predicted functions for five genes, with experimental validation reported for all five. Two previously uncharacterized genes, YJR120W and YDL157C, were predicted to modulate mitochondrial translation; functions were also predicted and validated for SDH9, ISC1 and FMP52. The study additionally validated previously unrecognized protein links to citrate.

Technology: MIMaL: ExtraTrees regression of metabolite abundance from proteomic profiles, SHAP interpretation, and UMAP/OPTICS clustering of protein-control profiles

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: MIMaL used tree-based regression and SHAP interpretation on yeast proteome/metabolome measurements, then clustered protein-control profiles across single-gene knockouts.
  • Still unknown: This was a yeast study using a prior 174-single-gene-knockout multi-omics dataset, with 348 condition profiles; it does not establish corresponding human gene functions. Five gene functions are reported validated, and the article specifically states YJR120W and YDL157C modulate mitochondrial translation. Some experimental validation used existing knockout strains and measurements; no independent replication is implied.
  • AI role: A tree-based model predicted metabolite profiles from proteomic measurements; SHAP-derived protein-control values and clustering across knockout conditions were used to infer new protein–metabolite connections and gene functions. The researchers experimentally validated predicted citrate-control relationships and five gene-function predictions.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9801967/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 81 of works of the same type, year and subfield (OpenAlex work metrics, 25 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.